Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HCB-101 is an anticodon engineered tRNA designed to suppress nonsense mutations & is delivered as a lipid nanoparticle to target the liver,where Factor VIII is produced. It is being evaluated for the treatment of severe hemophilia A.
Lead Product(s): HCB-101
Therapeutic Area: Genetic Disease Product Name: HCB-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
Through the acquisition, the combined company will advance the development of first-in-class tRNA-based therapeutics to target genetic disease and cancer.
Lead Product(s): tRNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: 4SR Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2023
Details:
hC Bio’s innovations in precision protein editing therapies target genetically-defined diseases including cancer. A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
Lead Product(s): Engineered tRNA-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Taiho Ventures
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 04, 2022
Details:
hC Bio is simultaneously developing a second tRNA-based platform called SWTX (“Switch”) to target diseases caused by missense mutations. This technology is designed to correct for such mutations in proteins that cause disease.
Lead Product(s): tRNA-based Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 23, 2022